Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ibandronate [ibandronic acid] with or without capecitabine in elderly patients with early breast cancer

Trial Profile

Ibandronate [ibandronic acid] with or without capecitabine in elderly patients with early breast cancer

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 10 Oct 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Capecitabine (Primary) ; Ibandronic acid; Ibandronic acid
  • Indications Carcinoma; Early breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ICE
  • Most Recent Events

    • 07 Sep 2023 Results(n=1409) published in the European Journal of Cancer.
    • 14 Dec 2019 Results (N= 15,457), a metanalysis of prospective randomized trials assessing efficacy of Capecitabine as a part of neo adjuvant or adjuvant therapy in patients with early breast cancer, presented at the 42nd Annual San Antonio Breast Cancer Symposium
    • 13 Dec 2014 Results presented at the 37th Annual San Antonio Breast Cancer Symposium.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top